1-[5-tert-butyl-2-(2-methylpyridin-5-yl)-2H-pyrazol-3-yl]-3-[4-(2-pyridin-4-yl-ethoxy)naphthalen-1-yl]-urea

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 1-[5-tert-butyl-2-(2-methylpyridin-5-yl)-2H-pyrazol-3-yl]-3-[4-(2-pyridin-4-yl-ethoxy)naphthalen-1-yl]-urea
• 英文别名: 1-[5-tert-butyl-2-(2-methylpyridin-5-yl)-2H-pyrazol-3-yl]-3-[4-(2-pyridin-4-ethoxy)naphthalen-1-yl]-urea；1-[5-Tert-butyl-2-(6-methylpyridin-3-yl)pyrazol-3-yl]-3-[4-(2-pyridin-4-ylethoxy)naphthalen-1-yl]urea
• 化学式: C₃₁H₃₂N₆O₂
• 分子量: 520.634
• InChiKey: APRDOMOEBUWBDX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.9
• 重原子数：
  39
• 可旋转键数：
  8
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  94
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• Fluorenecarboxylic acid esters, process for the manufacture thereof, and use thereof as medicaments
  申请人：Boehringer Ingelheim Pharma KG

  公开号：US20030199539A1

  公开（公告）日：2003-10-23

  Flourenecarboxylic acid esters of general formula 1 1 wherein X − and the groups A, R, R 1 , R 2 , R 3 , R 3′ , R 4 , and R 4′ have the meanings given in the claims and in the specification, processes for the manufacture thereof and the use thereof as medicaments.

  通用公式1的氟苯甲酸酯 其中X − 和基团A、R、R 1 、R 2 、R 3 、R 3′ 、R 4 和R 4′ 具有索赔和规范中给定的含义，其制造过程以及作为药物的用途。
• Methods of treating cytokine mediated diseases
  申请人：Boehringer Ingelheim Pharmaceuticals, Inc.

  公开号：US20030130309A1

  公开（公告）日：2003-07-10

  Disclosed are methods of treating certain cytokine mediated diseases or conditions using novel aromatic heterocyclic compounds of the formula(I) wherein Ar 1 ,Ar 2 ,L,Q and X are described herein. 1

  披露了使用公式(I)中描述的新芳香杂环化合物治疗特定细胞因子介导的疾病或症状的方法，其中Ar1，Ar2，L，Q和X如下所述。
• New difurylglycolic acid esters, processes for the preparation thereof as well as the use thereof as pharmaceutical compositions
  申请人：Boehringer Ingelheim Pharma GmbH & Co. KG

  公开号：US20030229227A1

  公开（公告）日：2003-12-11

  Difurylglycolic acid esters of the formula 1 1 wherein X − and the groups A, R, R 1 , R 2 , R 3 and R 3′ may have the meanings given in the claims and in the specification, processes for preparing them and their use for treating asthma, COPD, vagally induced sinus bradycardia, heart rhythm disorders, spasms in the gastrointestinal tract, spasms in the urinary tract or menstrual pain.

  Difurylglycolic acid esters of the formula 11其中X-和A、R、R1、R2、R3和R3'可能具有索赔和说明中给定的含义，用于制备它们的方法以及它们用于治疗哮喘、COPD、迷走神经引起的窦性心动过缓、心律失常、胃肠道痉挛、尿道痉挛或经期疼痛。
• Anticoagulant and fibrinolytic therapy uning p38 MAP kinase inhibitors
  申请人：Boehringer Ingelheim Pharmaceuticals, Inc.

  公开号：US20040033222A1

  公开（公告）日：2004-02-19

  Disclosed are methods for a treating a disease or condition relating to blood coagulation and fibrinolysis using p38 MAP kinase inhibitors.

  揭示了利用p38 MAP激酶抑制剂治疗与血液凝血和纤溶有关的疾病或症状的方法。
• INHIBITORS OF PHOSPHODIESTERASE TYPE-IV
  申请人：Rudra Sonali

  公开号：US20110021473A1

  公开（公告）日：2011-01-27

  The present invention relates to catechol derivatives of formula (I), which can be used as inhibitors of phosphodiesterase (PDPI) type 4 or type 7, Compounds disclosed herein can be useful in the treatment of CNS disorders, inflammatory diseases such as, AIDS, asthma, arthritis, bronchitis, chronic obstructive pulmonary disease (COPD), psoriasis, allergic rhinitis, shock, atopic dermatitis, Crohn's disease, adult respiratory distress syndrome (ARDS), eosinophilic granuloma, allergic conjunctivitis, osteoarthritis, ulcerative colitis and other inflammatory diseases especially in humans. Processes for the preparation of disclosed compounds are provided, as well as pharmaceutical compositions containing the disclosed compounds, and their use as phosphodiesterase (PDE) type 4 or type 7 inhibitors.

  本发明涉及公式（I）的邻苯二酚衍生物，可用作磷酸二酯酶（PDPI）类型4或类型7的抑制剂。本文披露的化合物可用于治疗中枢神经系统疾病、炎症性疾病，如艾滋病、哮喘、关节炎、支气管炎、慢性阻塞性肺病（COPD）、牛皮癣、过敏性鼻炎、休克、特应性皮炎、克罗恩病、成人呼吸窘迫综合征（ARDS）、嗜酸性肉芽肿、过敏性结膜炎、骨关节炎、溃疡性结肠炎和其他炎症性疾病，尤其是在人类身上。提供了用于制备所述化合物的方法，以及含有所述化合物的药物组合物，以及它们作为磷酸二酯酶（PDE）类型4或类型7抑制剂的用途。